Monovalent ligands of the human CD28 receptor
US8785138B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 8, 2010 |
| Grant date | Jul 22, 2014 |
| Priority date | — |
| Expiry date | Oct 8, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.